Prostatic Acid Phosphatase (PAP) by Immunohistochemistry

Also known as: PAP IHC

Clinical Use

Use

The Prostatic Acid Phosphatase (PAP) test by Immunohistochemistry is utilized to detect the presence of the PAP protein in tissue samples. It is significant in the diagnosis and management of prostate cancer, aiding in the identification of primary or metastatic prostatic carcinoma by highlighting cancerous prostatic cells within the examined tissue. The presence and abundance of PAP can provide information on the presence and extent of prostate cancer, guiding clinical treatment decisions.

Special Instructions

Not provided.

Limitations

It is important to note that the results of the Prostatic Acid Phosphatase (PAP) by IHC can be affected by the quality and representativeness of the specimen. Non-representative tissue types and depleted specimens can lead to unreliable results. Accurate interpretation requires proper specimen handling and preparation, adhering to provided guidelines, and considering the clinical context and other diagnostic findings.

Test Details

New York Approved

Methodology

Immunoassay (IHC)

Biomarkers

Prostatic Acid Phosphatase

Protein

IHC

Expression • Categorical (e.g., Positive / Negative / Indeterminate)

LOINC Codes

Result Codes

94736-6 - Tissue block ID Spec

Result Turnaround Time

1-3 days

Specimen

Tissue (FFPE)

Volume

Not provided

Minimum Volume

2 slides

Container

tissue transport kit (ARUP supply #47808)

Collection Instructions

Formalin fix (10 percent neutral buffered formalin) and paraffin embed specimen (cells must be prepared into a cellblock). Transport tissue block or 5 unstained (3- to 5-micron thick sections), positively charged slides.